This study is currently not recruiting participants.

A Multicenter Randomized Double-Blind Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects with Secondary Progressive Multiple Sclerosis

Study on Investigational Medication for Secondary Progressive Multiple Sclerosis

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The purpose of this study is to find out if BG00012 (Tecfidera) is effective in slowing the progression of disability in subjects with Secondary Progressive Multiple Sclerosis (SPMS).

Detailed description of study

The purpose of this study is to find out if BG00012 (Tecfidera) is effective in slowing the progression of disability in subjects with Secondary Progressive Multiple Sclerosis (SPMS).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: multiple sclerosis
  • Age: 100 years or below
  • Gender: All

This study investigates the effectiveness of an investigational medication in slowing down disability progression in individuals with Secondary Progressive Multiple Sclerosis (SPMS). Multiple Sclerosis is a condition that affects the brain and spinal cord, leading to a range of symptoms including physical, mental, and sometimes psychiatric problems.

Participants in this study will take either the investigational medication or a placebo, which is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will compare the outcomes between these two study arms to determine the medication's effectiveness.

  • Who can participate: Eligibility criteria details are not provided.
  • Study details: Participants will either receive the investigational medication or a placebo.
Updated on 19 Feb 2024. Study ID: 1502691402

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team